Trade Pliant Therapeutics, Inc. - PLRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.4 |
| Open | 1.39 |
| 1-Year Change | -89.48% |
| Day's Range | 1.37 - 1.44 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 1.41 | 0.02 | 1.44% | 1.39 | 1.45 | 1.37 |
| Apr 16, 2025 | 1.40 | 0.02 | 1.45% | 1.38 | 1.42 | 1.36 |
| Apr 15, 2025 | 1.41 | 0.07 | 5.22% | 1.34 | 1.42 | 1.34 |
| Apr 14, 2025 | 1.37 | 0.06 | 4.58% | 1.31 | 1.39 | 1.27 |
| Apr 11, 2025 | 1.29 | 0.07 | 5.74% | 1.22 | 1.29 | 1.20 |
| Apr 10, 2025 | 1.21 | -0.02 | -1.63% | 1.23 | 1.25 | 1.19 |
| Apr 9, 2025 | 1.26 | 0.09 | 7.69% | 1.17 | 1.29 | 1.06 |
| Apr 8, 2025 | 1.18 | -0.06 | -4.84% | 1.24 | 1.26 | 1.16 |
| Apr 7, 2025 | 1.20 | -0.03 | -2.44% | 1.23 | 1.32 | 1.16 |
| Apr 4, 2025 | 1.29 | 0.04 | 3.20% | 1.25 | 1.30 | 1.20 |
| Apr 3, 2025 | 1.27 | -0.04 | -3.05% | 1.31 | 1.31 | 1.24 |
| Apr 2, 2025 | 1.36 | 0.07 | 5.43% | 1.29 | 1.41 | 1.28 |
| Apr 1, 2025 | 1.33 | 0.06 | 4.72% | 1.27 | 1.36 | 1.20 |
| Mar 31, 2025 | 1.31 | -0.07 | -5.07% | 1.38 | 1.39 | 1.29 |
| Mar 28, 2025 | 1.42 | -0.05 | -3.40% | 1.47 | 1.51 | 1.42 |
| Mar 27, 2025 | 1.46 | 0.05 | 3.55% | 1.41 | 1.48 | 1.40 |
| Mar 26, 2025 | 1.43 | -0.02 | -1.38% | 1.45 | 1.47 | 1.37 |
| Mar 25, 2025 | 1.44 | -0.12 | -7.69% | 1.56 | 1.56 | 1.43 |
| Mar 24, 2025 | 1.55 | 0.00 | 0.00% | 1.55 | 1.61 | 1.51 |
| Mar 21, 2025 | 1.51 | 0.01 | 0.67% | 1.50 | 1.61 | 1.48 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Pliant Therapeutics, Inc. Company profile
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Pliant Therapeutics Inc revenues decreased 82% to $7.6M. Net loss increased from $41.5M to $97.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 14% to $73.6M (expense), General and administrative - Balancing increase of 39% to $21M (expense).
| Industry: | Pharmaceuticals (NEC) |
260 Littlefield Avenue
Suite 150
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com